SCHEMBL6889633

SCHEMBL6889633

O=C(OCI)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.64
SLC1A5 Q15758 1/20 0.58
PDCD1 Q15116 1/20 0.53
CD274 Q9NZQ7 1/20 0.53
ALDH1A1 P00352 1/20 0.51
NPY1R P25929 1/20 0.51
NPY2R P49146 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
TDP1 Q9NUW8 2/20 0.50
LMNA P02545 1/20 0.49
MAPT P10636 3/20 0.48
KMT2A Q03164 2/20 0.48
MAPK1 P28482 1/20 0.48
HIF1A Q16665 1/20 0.48
PTPN1 P18031 1/20 0.48
GSK3B P49841 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A3 Q01959 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18145 0.88 TDP1 (0.63) KDM4EALDH1A1SMN1; SMN2TDP1LMNA
SCHEMBL13291800 0.82 KDM4E (0.66) KDM4ESLC1A5PDCD1CD274ALDH1A1
Chloroform SCHEMBL8308271 0.81 ALDH1A1 (0.56) KDM4EALDH1A1TDP1LMNAKMT2A
SCHEMBL27833464 0.81 KDM4E (0.69) KDM4ESLC1A5PDCD1CD274ALDH1A1
SCHEMBL570961 0.81 MEN1 (0.70) KDM4ESLC1A5PDCD1CD274ALDH1A1
SCHEMBL24106782 0.81 MEN1 (0.70) KDM4ESLC1A5PDCD1CD274ALDH1A1
SCHEMBL28455123 0.80 TDP1 (0.64) KDM4ESLC1A5PDCD1CD274ALDH1A1
SCHEMBL9537746 0.79 KMT2A (0.79) KDM4ESLC1A5ALDH1A1SMN1; SMN2TDP1
SCHEMBL17736345 0.79 KDM4E (0.62) KDM4ESLC1A5PDCD1CD274ALDH1A1
SCHEMBL14231645 0.79 KDM4E (0.62) KDM4ESLC1A5PDCD1CD274ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 KDM4E 1406/4885SLC1A5 1205/4885PDCD1 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.